109 related articles for article (PubMed ID: 8658671)
1. Factors affecting therapeutic effect of anti-CD3 and CD4 monoclonal antibody in acute renal allograft rejection.
Wang XH; Xie T
Transplant Proc; 1996 Jun; 28(3):1306-8. PubMed ID: 8658671
[TBL] [Abstract][Full Text] [Related]
2. Anti-CD3 and -CD4 monoclonal antibody in the treatment of steroid-resistant renal allograft rejection.
Wang XH; Xie T
Chin Med J (Engl); 1993 Nov; 106(11):821-4. PubMed ID: 8143493
[TBL] [Abstract][Full Text] [Related]
3. Anti-CD4 monoclonal antibody therapy of late acute rejection in renal allograft recipients--CD4+ T cells play an essential role in the rejection process.
Reinke P; Kern F; Fietze E; Döcke WD; Ewert R; Emmrich F; Volk HD
Transplant Proc; 1995 Feb; 27(1):859-62. PubMed ID: 7879207
[No Abstract] [Full Text] [Related]
4. Devising murine models to better adapt clinical protocols: sequential low-dose treatment with anti-CD3 and anti-CD4 monoclonal antibodies to prevent fully mismatched allograft rejection.
Campos HH; Bach JF; Chatenoud L
Transplant Proc; 1993 Feb; 25(1 Pt 1):798-9. PubMed ID: 8438486
[No Abstract] [Full Text] [Related]
5. Treatment with OKT3 and cyclosporine for acute allograft rejection.
Schulak JA; Mayes JT; Hricik DE
Transplant Proc; 1991 Aug; 23(4):2119-22. PubMed ID: 1908150
[TBL] [Abstract][Full Text] [Related]
6. CD69 expression on peripheral CD8 T cells correlates with acute rejection in renal transplant recipients.
Posselt AM; Vincenti F; Bedolli M; Lantz M; Roberts JP; Hirose R
Transplantation; 2003 Jul; 76(1):190-5. PubMed ID: 12865808
[TBL] [Abstract][Full Text] [Related]
7. Targeting acute allograft rejection by immunotherapy with ex vivo-expanded natural CD4+ CD25+ regulatory T cells.
Xia G; He J; Zhang Z; Leventhal JR
Transplantation; 2006 Dec; 82(12):1749-55. PubMed ID: 17198271
[TBL] [Abstract][Full Text] [Related]
8. Immunological analysis of kidney allograft infiltrates during rejection: presence of cells coexpressing CD4 and CD8 antigens.
Trovati A; Cinti P; Tamburro ML; Lattanzi R; Baiano V; Orlandini AM; Renna Molajoni E; Cortesini R
Transplant Proc; 1995 Feb; 27(1):930-1. PubMed ID: 7879236
[No Abstract] [Full Text] [Related]
9. FK 506 therapy for refractory renal allograft rejection: lessons from liver transplantation.
Woodle ES; Bruce DS; Josephson M; Newell KA; Piper JB; Millis JM; Cronin D; Whitman G; Ruebe M; Thistlethwaite JR
Clin Transplant; 1996 Aug; 10(4):323-32. PubMed ID: 8884103
[TBL] [Abstract][Full Text] [Related]
10. CD4 monoclonal antibodies in the preclinical dog renal allograft model.
Watson CJ; Davies HS; Metcalfe SM; Cobbold SP; Rebello PR; Collier DS; Waldmann H; Calne RY
Transplant Proc; 1993 Feb; 25(1 Pt 1):804-6. PubMed ID: 8438491
[No Abstract] [Full Text] [Related]
11. Sparing of first dose effect of monovalent anti-CD3 antibody used in allograft rejection is associated with diminished release of pro-inflammatory cytokines.
Abbs IC; Clark M; Waldmann H; Chatenoud L; Koffman CG; Sacks SH
Ther Immunol; 1994 Dec; 1(6):325-31. PubMed ID: 7584508
[TBL] [Abstract][Full Text] [Related]
12. Prevention of acute murine cardiac allograft rejection: anti-CD4 or anti-vascular cell adhesion molecule one monoclonal antibodies block acute rejection but permit persistent graft-reactive alloimmunity and chronic tissue remodelling.
Orosz CG; Huang EH; Bergese SD; Sedmak DD; Birmingham DJ; Ohye RG; VanBuskirk AM
J Heart Lung Transplant; 1997 Sep; 16(9):889-904. PubMed ID: 9322138
[TBL] [Abstract][Full Text] [Related]
13. Immunohistological analysis of T lymphocyte subpopulations in needle core biopsies from OKT3-treated renal allograft recipients.
Chauhan B; Mohanakumar T; Flye MW
Transplantation; 1990 Dec; 50(6):1058-60. PubMed ID: 2147792
[No Abstract] [Full Text] [Related]
14. OKT3 escalating dose regimens provide effective therapy for renal allograft rejection.
Woodle ES; Bruce DS; Josephson M; Cronin D; Newell KA; Millis JM; Piper JB; O'Laughlin R; Thistlethwaite JR
Clin Transplant; 1996 Aug; 10(4):389-95. PubMed ID: 8884115
[TBL] [Abstract][Full Text] [Related]
15. Anti-CD4 monoclonal antibody therapy.
Delmonico FL; Cosimi AB
Clin Transplant; 1996 Oct; 10(5):397-403. PubMed ID: 8930451
[TBL] [Abstract][Full Text] [Related]
16. Pharmacodynamic effects of everolimus on anti-CD3 antibody-stimulated T-lymphocyte proliferation and interleukin-10 synthesis in stable kidney-transplant patients.
Böhler T; Waiser J; Lichter S; Schumann B; Neumayer HH; Kamar N; Budde K
Cytokine; 2008 Jun; 42(3):306-11. PubMed ID: 18440821
[TBL] [Abstract][Full Text] [Related]
17. Successful treatment of renal allograft rejection with a humanized antilymphocyte monoclonal antibody.
Friend PJ; Rebello P; Oliveira D; Manna V; Cobbold SP; Hale G; Jamieson NV; Jamieson I; Calne RY; Harris DT
Transplant Proc; 1995 Feb; 27(1):869-70. PubMed ID: 7879212
[No Abstract] [Full Text] [Related]
18. New immunosuppressive therapies in renal transplantation: monoclonal antibodies.
Buhaescu I; Segall L; Goldsmith D; Covic A
J Nephrol; 2005; 18(5):529-36. PubMed ID: 16299678
[TBL] [Abstract][Full Text] [Related]
19. Effect of prophylaxis with low-dose anti-thymocyte globulin on prevention of acute kidney allograft rejection.
Khosroshahi HT; Tubbs RS; Shoja MM; Ghafari A; Noshad H; Ardalan MR
Transplant Proc; 2008; 40(1):137-9. PubMed ID: 18261569
[TBL] [Abstract][Full Text] [Related]
20. Immunoexpression of perforin and granzyme B on infiltrating lymphocytes in human renal acute allograft rejection.
Wagrowska-Danilewicz M; Danilewicz M
Nefrologia; 2003; 23(6):538-44. PubMed ID: 15002789
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
